Market Cap 138.44B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 7.94
Forward PE 7.93
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 27,669,574
Avg Vol 39,788,496
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 24%
Beta 0.34
Analysts Sell
Price Target $29.20

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
woolybully
woolybully Jun. 29 at 7:03 PM
1 · Reply
morgangj
morgangj Jun. 29 at 6:58 PM
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Jun. 29 at 6:58 PM
$PFE gap near 26.
1 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 6:14 PM
$PFE the most Pfizer shit ever
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 6:13 PM
$PFE lmfao it can’t ever hold any gains
0 · Reply
sethmarcus
sethmarcus Jun. 29 at 5:25 PM
0 · Reply
LoneBroker
LoneBroker Jun. 29 at 5:21 PM
$PFE $24.29 🐻 • RSI 35.71 • ATR% 2.38 • vol↓ Support & Resistance — UPDATED 2026-06-26 3 Days | Support: $23.62 – $23.62 | Resistance: $25.11 – $25.11 5 Days | Support: $23.62 – $23.62 | Resistance: $25.31 – $25.31 7 Days | Support: $23.62 – $23.62 | Resistance: $26.28 – $26.28 20 Days | Support: $23.62 – $23.62 | Resistance: $26.49 – $26.49 60 Days | Support: $23.62 – $23.62 | Resistance: $28.75 – $28.75 100 Days | Support: $23.62 – $23.62 | Resistance: $28.75 – $28.75 200 Days | Support: $23.58 – $23.58 | Resistance: $28.75 – $28.75 Momentum leans bearish with RSI at 35.71. Volatility sits at 2.38% ATR, indicating contraction. Volume shows vol↓, signaling trader attention to recent flow. -------------------------- 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 1:00 PM PT
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 4:51 PM
$PFE hey LLY is green again :)
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jun. 29 at 4:50 PM
$PFE - Cursed Straße
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 29 at 4:44 PM
$PFE How about a little Pfizer trivia for our Monday. Over the last 5 years, what # do we rank on the s&p for performance?
3 · Reply
Latest News on PFE
Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 4 days ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 5 days ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer (PFE) Shares Sink After Surprise CFO Exit

2026-06-18T18:35:11.000Z - 11 days ago

Pfizer (PFE) Shares Sink After Surprise CFO Exit


Pfizer reaffirms all components of FY26 guidance

2026-06-18T17:30:31.000Z - 11 days ago

Pfizer reaffirms all components of FY26 guidance


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 11 days ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 11 days ago

Pfizer Announces Chief Financial Officer Transition


Pfizer says FDA approves expanded indication for Hympavzi

2026-06-08T10:51:57.000Z - 21 days ago

Pfizer says FDA approves expanded indication for Hympavzi


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 21 days ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer presents results from Phase 2b studies of berobenatide

2026-06-07T22:00:49.000Z - 21 days ago

Pfizer presents results from Phase 2b studies of berobenatide


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 23 days ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 23 days ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 23 days ago

Pfizer Press release: Study update


Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 4 weeks ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA


Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 7 weeks ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC


Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 7 weeks ago

Pfizer CEO on AI-designed molecule, and race to use new tech


3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 7 weeks ago

3 Dividend Stocks for May 2026

SYY WSO


Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings Call Transcript: Q1 2026


Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Earnings release: Q1 2026


Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Quarterly report: Q1 2026


Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 7 weeks ago

Pfizer Slides: Q1 2026


Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 7 weeks ago

Pfizer Posts Better-Than-Expected Revenue, Profit


Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 7 weeks ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS


US FDA approves Pfizer, Arvinas' breast cancer drug

May 1, 2026, 12:37 PM EDT - 2 months ago

US FDA approves Pfizer, Arvinas' breast cancer drug

ARVN


woolybully
woolybully Jun. 29 at 7:03 PM
1 · Reply
morgangj
morgangj Jun. 29 at 6:58 PM
0 · Reply
_Crim_Jamer_
_Crim_Jamer_ Jun. 29 at 6:58 PM
$PFE gap near 26.
1 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 6:14 PM
$PFE the most Pfizer shit ever
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 6:13 PM
$PFE lmfao it can’t ever hold any gains
0 · Reply
sethmarcus
sethmarcus Jun. 29 at 5:25 PM
0 · Reply
LoneBroker
LoneBroker Jun. 29 at 5:21 PM
$PFE $24.29 🐻 • RSI 35.71 • ATR% 2.38 • vol↓ Support & Resistance — UPDATED 2026-06-26 3 Days | Support: $23.62 – $23.62 | Resistance: $25.11 – $25.11 5 Days | Support: $23.62 – $23.62 | Resistance: $25.31 – $25.31 7 Days | Support: $23.62 – $23.62 | Resistance: $26.28 – $26.28 20 Days | Support: $23.62 – $23.62 | Resistance: $26.49 – $26.49 60 Days | Support: $23.62 – $23.62 | Resistance: $28.75 – $28.75 100 Days | Support: $23.62 – $23.62 | Resistance: $28.75 – $28.75 200 Days | Support: $23.58 – $23.58 | Resistance: $28.75 – $28.75 Momentum leans bearish with RSI at 35.71. Volatility sits at 2.38% ATR, indicating contraction. Volume shows vol↓, signaling trader attention to recent flow. -------------------------- 📌 RSI = momentum (0–100). >50 = strength, <50 = weakness 📌 ATR% = daily volatility (higher = bigger swings) 📌 Legend: 🐂 bullish • 🐻 bearish • 😐 neutral • vol↑ rising volume • vol↓ easing volume ⏳ Valid until: 1:00 PM PT
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 4:51 PM
$PFE hey LLY is green again :)
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Jun. 29 at 4:50 PM
$PFE - Cursed Straße
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 29 at 4:44 PM
$PFE How about a little Pfizer trivia for our Monday. Over the last 5 years, what # do we rank on the s&p for performance?
3 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 4:10 PM
$PFE I don’t think the market could be any more clear that it wants a new CEO
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 3:43 PM
$PFE $SLS #1 Trending on Stocktwits WHY IT'S TRENDING SELLAS Life Sciences is surging as investors anticipate pivotal phase 3 clinical trial results, fueled by a high-pressure short squeeze environment and heavy institutional interest in its potential oncology breakthroughs. Community sentiment is overwhelmingly bullish, with active discussions focusing on the high cost to borrow shares, the scarcity of available short positions, and expectations for a major corporate catalyst. ✌️🙏❤️‍🩹
0 · Reply
kicker911
kicker911 Jun. 29 at 3:38 PM
$PFE honestly seems way undervalued, safe and has a good dividend. Anything between 21-24 seems like a safe price on this stock.
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 3:31 PM
$PFE buying doge coin when I bought PFE would have been a better investment…
1 · Reply
MrPeanutEsquire
MrPeanutEsquire Jun. 29 at 3:25 PM
$PFE Just a little red. It could happen to anyone
1 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 3:06 PM
$PFE genuinely what now
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 3:03 PM
$PFE worthless
0 · Reply
saifnila2
saifnila2 Jun. 29 at 2:58 PM
$PFE what a terrible pos is boula. No insight, a fuking fool.
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:33 PM
$SLS $PFE Pfizer has been making all the right moves in preparation of SLS BO since December 2025. Pfizer in January 2026 appointed Michael Burns brother of Sellas CFO John Burns as Senior Medical Director of Oncology Late Development, coming directly from oncology early development at AbbVie. Someone who spent their career in the belly of the beast understanding exactly how AbbVie develops oncology assets, exactly where the gaps in the Venetoclax franchise are, and exactly what kind of validated late stage asset Pfizer needs to compete in hematologic malignancies just walked through Pfizer's door. Pfizer didn't hire a hematology focused Chief Oncology Officer from Novartis and then bring in a Senior Medical Director of Late Development from AbbVie's oncology early development team by accident. That's a deliberate and coordinated build of expertise in precisely the space that Sellas GPS and 009 are about to disrupt. CEO Dr. Bourla and CEO Stergiou are friends. ✌️🙏❤️‍🩹
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:28 PM
$ABBV $PFE $RVMD $SLS 10 Million Volume in first full hours of trading. Word of a CURATIVE cancer platform that can tackle 20+ WT1 cancers GPS is spreading on Wall Street just a few blocks away from Sellas Headquarters in N.Y ✌️🙏❤️‍🩹
0 · Reply
Micheal_Pothead
Micheal_Pothead Jun. 29 at 2:27 PM
$PFE 24.50
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 29 at 2:21 PM
$ABBV $PFE $RVMD $SLS 0 Shares Available 👇 going to in to the biggest Catalyst in Sellas Corporate history with 63 Million short shares trapped. 👇 ✌️🙏❤️‍🩹
0 · Reply